Tiziana Life Sciences Ltd (NASDAQ:TLSA) — Market Cap & Net Worth
Market Cap & Net Worth: Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has a market capitalization of $113.26 Million ($113.26 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18816 globally and #4364 in its home market, demonstrating a -4.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tiziana Life Sciences Ltd's stock price $0.89 by its total outstanding shares 127259131 (127.26 Million). Also see total assets of Tiziana Life Sciences Ltd for a full breakdown of the balance sheet.
Tiziana Life Sciences Ltd Market Cap History: 2018 to 2026
Tiziana Life Sciences Ltd's market capitalization history from 2018 to 2026. Data shows change from $187.94 Million to $113.26 Million (-7.63% CAGR). Also see TLSA operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Tiziana Life Sciences Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #533 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1824 of 3165 |
Weight: Tiziana Life Sciences Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tiziana Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tiziana Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Tiziana Life Sciences Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TLSA by Market Capitalization
Companies near Tiziana Life Sciences Ltd in the global market cap rankings as of September 18, 2026. Review TLSA tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tiziana Life Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Tiziana Life Sciences Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Tiziana Life Sciences Ltd's market cap moved from $187.94 Million to $ 113.26 Million, with a yearly change of -7.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $113.26 Million | -40.27% |
| 2025 | $189.62 Million | +114.02% |
| 2024 | $88.60 Million | +24.32% |
| 2023 | $71.27 Million | -6.43% |
| 2022 | $76.16 Million | -37.66% |
| 2021 | $122.17 Million | -52.05% |
| 2020 | $254.77 Million | +87.03% |
| 2019 | $136.22 Million | -27.52% |
| 2018 | $187.94 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Tiziana Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $113.26 Million USD |
| MoneyControl | $113.26 Million USD |
| MarketWatch | $113.26 Million USD |
| marketcap.company | $113.26 Million USD |
| Reuters | $113.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more